Zacks: Brokerages Anticipate CRISPR Therapeutics AG (NASDAQ:CRSP) Will Announce Earnings of -$1.68 Per Share

Equities research analysts expect CRISPR Therapeutics AG (NASDAQ:CRSP) to announce ($1.68) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for CRISPR Therapeutics’ earnings, with estimates ranging from ($1.83) to ($1.32). CRISPR Therapeutics reported earnings of ($1.32) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 27.3%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, October 27th.

According to Zacks, analysts expect that CRISPR Therapeutics will report full-year earnings of $4.81 per share for the current fiscal year, with EPS estimates ranging from $4.37 to $5.33. For the next financial year, analysts anticipate that the business will report earnings of ($7.24) per share, with EPS estimates ranging from ($8.70) to ($5.44). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, July 29th. The company reported $9.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.52 by $5.92. The firm had revenue of $900.70 million for the quarter, compared to the consensus estimate of $678.05 million. CRISPR Therapeutics had a return on equity of 24.08% and a net margin of 49.52%.

Several research firms have recently issued reports on CRSP. Canaccord Genuity upped their price objective on CRISPR Therapeutics from $151.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, August 16th. raised CRISPR Therapeutics from a “sell” rating to a “neutral” rating and upped their target price for the company from $55.00 to $132.00 in a research report on Monday, June 14th. TheStreet raised CRISPR Therapeutics from a “d” rating to a “c+” rating in a research report on Monday, August 9th. Citigroup raised CRISPR Therapeutics from a “sell” rating to a “neutral” rating and upped their target price for the company from $55.00 to $132.00 in a research report on Monday, June 14th. Finally, Chardan Capital decreased their target price on CRISPR Therapeutics from $175.00 to $171.00 and set a “buy” rating for the company in a research report on Friday, July 30th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $160.00.

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, August 4th. The stock was sold at an average price of $125.02, for a total value of $187,530.00. Following the transaction, the chief executive officer now directly owns 189,219 shares of the company’s stock, valued at $23,656,159.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Rodger Novak sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, June 30th. The shares were sold at an average price of $165.00, for a total value of $4,125,000.00. Following the completion of the transaction, the president now directly owns 573,007 shares in the company, valued at $94,546,155. The disclosure for this sale can be found here. Insiders sold 81,875 shares of company stock worth $12,146,610 in the last quarter. 10.70% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. Tradition Wealth Management LLC purchased a new stake in shares of CRISPR Therapeutics during the second quarter worth about $26,000. Arkadios Wealth Advisors purchased a new stake in shares of CRISPR Therapeutics during the second quarter worth about $27,000. RMR Wealth Builders bought a new stake in CRISPR Therapeutics in the first quarter valued at about $29,000. Ameritas Investment Company LLC bought a new stake in CRISPR Therapeutics in the first quarter valued at about $29,000. Finally, Eudaimonia Partners LLC acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $31,000. 52.68% of the stock is currently owned by institutional investors and hedge funds.

CRSP stock opened at $116.47 on Tuesday. The business’s fifty day moving average price is $124.54 and its 200 day moving average price is $124.17. The company has a market capitalization of $8.88 billion, a PE ratio of 22.79 and a beta of 2.25. CRISPR Therapeutics has a 12-month low of $79.31 and a 12-month high of $220.20.

About CRISPR Therapeutics

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

See Also: What is basic economics?

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.